APA

Bjorklund C. C., Lu L., Kang J., Hagner P. R., Havens C. G., Amatangelo M., Wang M., Ren Y., Couto S., Breider M., Ning Y., Gandhi A. K., Daniel T. O., Chopra R., Klippel A. & Thakurta A. G. (20160125). Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. : Blood cancer journal.

Chicago

Bjorklund C C, Lu L, Kang J, Hagner P R, Havens C G, Amatangelo M, Wang M, Ren Y, Couto S, Breider M, Ning Y, Gandhi A K, Daniel T O, Chopra R, Klippel A and Thakurta A G. 20160125. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. : Blood cancer journal.

Harvard

Bjorklund C. C., Lu L., Kang J., Hagner P. R., Havens C. G., Amatangelo M., Wang M., Ren Y., Couto S., Breider M., Ning Y., Gandhi A. K., Daniel T. O., Chopra R., Klippel A. and Thakurta A. G. (20160125). Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. : Blood cancer journal.

MLA

Bjorklund C C, Lu L, Kang J, Hagner P R, Havens C G, Amatangelo M, Wang M, Ren Y, Couto S, Breider M, Ning Y, Gandhi A K, Daniel T O, Chopra R, Klippel A and Thakurta A G. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. : Blood cancer journal. 20160125.